<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916406</url>
  </required_header>
  <id_info>
    <org_study_id>C1061016</org_study_id>
    <secondary_id>2019-000929-42</secondary_id>
    <nct_id>NCT03916406</nct_id>
  </id_info>
  <brief_title>THE EFFECT OF MULTIPLE DOSES OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL MIDAZOLAM DOSE IN HEALTHY PARTICIPANTS</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, OPEN LABEL, 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF REPEATED DOSING OF PF-06835919 ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF MIDAZOLAM IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, open label, 2 way crossover drug drug interaction (DDI) study
      which will evaluate the impact of PF 06835919 on midazolam pharmacokinetics in healthy
      participants. Participants will be randomized to 1 of 2 treatment sequences as described
      below. A total of approximately 10 healthy male and/or female participants will be enrolled
      in this study so that approximately 5 participants will be enrolled into each treatment
      sequence. In this crossover study, 2 treatments are being assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2019</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">June 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf of midazolam following a single oral dose</measure>
    <time_frame>Baseline up to 51 days</time_frame>
    <description>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast of midazolam following a single oral dose.</measure>
    <time_frame>Baseline up to 51 days</time_frame>
    <description>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of midazolam following a single oral dose.</measure>
    <time_frame>Baseline up to 51 days</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events in participants</measure>
    <time_frame>Screening up to 79 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>midazolam alone followed by combination of PF 06835919 and midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF 06835919 in combination with midazolam followed by midazolam alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF 06835919</intervention_name>
    <description>300 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>7.5 mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female participants who are healthy as determined by medical evaluation
             including medical history, physical examination, laboratory tests, and cardiovascular
             tests.

          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;
             positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core
             antibody (HBcAb), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed

          -  Participants, who according to the product label for midazolam, would be at increased
             risk if dosed with midazolam (ie, including but not limited to participants with
             history of myasthenia gravis, chronic obstructive pulmonary disease (COPD), pulmonary
             insufficiency, glaucoma, concomitant central nervous system (CNS) depressants).

          -  History of hypersensitivity to midazolam or any other benzodiazepine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brussels Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <state>Be-bru</state>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C1061016&amp;StudyName=A+PHASE+1%2C+RANDOMIZED%2C+OPEN+LABEL%2C+2-WAY+CROSSOVER+STUDY+TO+EVALUATE+THE+EFFECT+OF+REPEATED+DOSING+OF+PF-06835919+ON+THE+PHARMACOKINETICS+OF+A+SINGLE+ORAL+DOSE+OF+MIDAZOLAM+IN+HEALTHY+PARTICIPANTS</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 12, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

